ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook Sells 400 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 400 shares of the business’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $53.92, for a total transaction of $21,568.00. Following the sale, the vice president now directly owns 55,588 shares in the company, valued at approximately $2,997,304.96. This represents a 0.71 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ ANIP opened at $53.93 on Tuesday. The company has a 50-day simple moving average of $56.58 and a 200-day simple moving average of $59.03. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The company has a market cap of $1.13 billion, a PE ratio of -98.05 and a beta of 0.73. ANI Pharmaceuticals, Inc. has a 12 month low of $52.50 and a 12 month high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, beating analysts’ consensus estimates of $1.09 by $0.25. The company had revenue of $148.30 million during the quarter, compared to the consensus estimate of $144.37 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The company’s quarterly revenue was up 12.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.05 EPS. On average, equities analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.87 earnings per share for the current year.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. Rhumbline Advisers raised its stake in shares of ANI Pharmaceuticals by 15.4% in the 2nd quarter. Rhumbline Advisers now owns 42,170 shares of the specialty pharmaceutical company’s stock valued at $2,685,000 after acquiring an additional 5,617 shares during the period. Arizona State Retirement System lifted its holdings in ANI Pharmaceuticals by 4.7% in the 2nd quarter. Arizona State Retirement System now owns 4,702 shares of the specialty pharmaceutical company’s stock worth $299,000 after buying an additional 211 shares in the last quarter. Quest Partners LLC purchased a new position in ANI Pharmaceuticals in the 2nd quarter valued at about $261,000. Texas Permanent School Fund Corp grew its stake in shares of ANI Pharmaceuticals by 1.3% during the second quarter. Texas Permanent School Fund Corp now owns 13,372 shares of the specialty pharmaceutical company’s stock valued at $852,000 after acquiring an additional 178 shares in the last quarter. Finally, American Century Companies Inc. increased its position in shares of ANI Pharmaceuticals by 99.2% during the second quarter. American Century Companies Inc. now owns 99,831 shares of the specialty pharmaceutical company’s stock worth $6,357,000 after acquiring an additional 49,717 shares during the last quarter. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Wall Street Analyst Weigh In

ANIP has been the topic of a number of research reports. HC Wainwright restated a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a report on Monday, November 11th. Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, December 11th. Leerink Partners began coverage on shares of ANI Pharmaceuticals in a report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 target price for the company. Raymond James upped their price target on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a report on Wednesday, September 18th. Finally, Truist Financial raised their price objective on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research note on Tuesday, October 22nd. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, ANI Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $77.71.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.